Curatis Advances C-PTBE-01 Toward Phase III Trial Following Positive FDA Meeting
核心洞察
Curatis achieved FDA alignment on Phase III trial design for C-PTBE-01 (corticorelin) to treat peritumoral brain edema (搜索) during a Type B meeting on September 9, 2025.
The company reported 14% year-over-year revenue growth to CHF 5.2 million in H1 2025, bolstered by a significant partnership with Phoenix Labs.
C-PTBE-01 demonstrated potential to substantially reduce or replace steroid use in PTBE patients, addressing a condition affecting over 150,000 patients in the US alone.
Curatis Holding AG (搜索) achieved a significant regulatory milestone for its lead drug candidate C-PTBE-01 (corticorelin), securing FDA alignment on Phase III trial design during a Type B meeting held on September 9, 2025. The positive outcome positions the Swiss pharmaceutical company to advance its treatment for peritumoral brain edema (搜索) (PTBE) into pivotal clinical testing.
The FDA meeting addressed key aspects of the planned Phase III clinical trial design as well as non-clinical and manufacturing considerations for corticorelin. According to the company, the outcome was positive, though detailed meeting minutes have not yet been released.
Addressing Significant Unmet Medical Need
C-PTBE-01 targets peritumoral brain edema (搜索), a condition that occurs in association with many primary and metastatic brain tumors (搜索), often connected to metastases from lung cancer (搜索), breast cancer (搜索), melanoma (搜索), and colorectal cancer (搜索). PTBE results in impairment of brain function due to extracellular fluid accumulation around tumors, causing symptoms including headaches, vomiting, and neurological dysfunction such as paralysis, speech disorders, visual problems, and altered mental status.
More than 150,000 patients in the United States alone suffer from PTBE. Current standard of care relies on corticosteroids (搜索), which frequently cause serious side effects including severe myopathy, impaired glucose metabolism, muscle wasting, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension, and personality changes. Additionally, corticosteroids can counteract certain cancer therapies, including chemotherapy and emerging immunotherapies that depend on adequate T-cell functionality.
Clinical Evidence and Mechanism
Corticorelin, a 41 amino acid endogenous polypeptide, demonstrated preclinical ability to positively impact the blood-brain barrier (搜索) after disruption due to underlying malignant tumors. In two clinical studies involving patients with PTBE, corticorelin showed potential to substantially reduce or, in some cases, completely replace steroid use, potentially reducing or avoiding severe glucocorticoid-related side effects and improving quality of life.
Business Performance and Strategic Initiatives
Curatis reported strong financial performance for the first half of 2025, with revenues reaching CHF 5.2 million, representing 14% year-over-year growth. Product sales accounted for CHF 5.0 million, while services revenues contributed CHF 0.2 million. The growth was supported by a significant partnership with Phoenix Labs, Ireland, adding four products that generated approximately CHF 5 million in revenues during 2024.
Despite revenue growth, the company recorded a loss of CHF 1.2 million for the period, primarily driven by increased development expenses for C-PTBE-01 in preparation for the planned Phase III clinical trial. Cash flow amounted to CHF -1.0 million, with the company maintaining a cash position of CHF 2.0 million.
Partnership Strategy and Outlook
In Q3 2025, Curatis began actively seeking global pharmaceutical partners for C-PTBE-01, focusing on companies active in oncology. The company anticipates continued growth in product and service revenues for 2025, primarily driven by new products, notably the four recently contracted products from Phoenix Labs in pain management and urology.
Curatis aims to achieve break-even results in 2026 through substantially increased revenues and cost reduction, regardless of whether a partner for C-PTBE-01 can be secured. The company's portfolio includes more than 40 products and a pipeline of orphan and specialty drugs for rare diseases and specialty care.